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INTRODUCTION
Rocuronium bromide is a non-depolarizing aminosteroidal
drug characterized by rapid onset and intermediate duration
of action. Pain is a common side effect of rocuronium injec-
tion, reported to occur in 50-80% of patients (1-3). Conscious
patients administered sub-paralyzing doses often suffer severe
burning sensation on injection of the drug (4). Even after loss
of consciousness, rocuronium injection causes a withdrawal
movement of the injected hand or arm. The pathophysiologic
mechanism of pain caused by the intravenous (IV) adminis-
tration of rocuronium injection remains unclear. Changes in
plasma histamine concentration after administration of rocuro-
nium are not significant (5). However, analysis of dermal mic-
rodialysis-induced mast cell stimulation reveals that high con-
centrations of rocuronium lead to significant increases in his-
tamine and tryptase release (6, 7). Histamine is widely known
for causing pruritus, rarely provokes pain (8), but high con-
centrations of histamine may activate polymodal nociceptors,
resulting in pain production (5, 9). Peripheral veins are inner-
vated with polymodal nociceptors that mediate the pain res-
ponse to the injection of rocuronium (6, 10). There are no
published studies on the incidence and degree of movement
against rocuronium injection pain after pretreatment with
antihistamines. This randomized, double-blind, placebo-con-
trolled study was designed to evaluate the effectiveness of
antihistamine pretreatment in reducing withdrawal move-
ments associated with the administration of rocuronium.
MATERIALS AND METHODS
A minimum sample size of 127 cases was required in this
study by a statistical power analysis (conducted with α =0.05,
power=0.80, and determined by the estimated relative pro-
portions in each category for each group using our observa-
tions). After institutional ethics committee approval and in-
formed patient consent were obtained, 171 patients (ages 18
to 65 yr, ASA physical status I or II, undergoing general anes-
thesia for elective surgery) were recruited for a prospective,
randomized, and blinded study. Exclusion criteria are; patients
with neurological deficits, opioid or local anesthetic allergies,
recent exposure to antihistamines or antidepressants, asthma,
pregnancy, those who received analgesics within the previous
24 hr, those with difficult venous access, and those requiring
rapid sequence induction. All patients were premedicated
with glycopyrrolate 0.2 mg and midazolam 2 mg intramus-
cularly 30 min before induction of anesthesia. Patients were
randomly allocated into two groups using a sealed envelope
system. The control group (n=79, group C) received 2 mL
of saline, and the antihistamine group (n=92, group A) received
pheniramine maleate 2 mL (45.5 mg) at the time of premed-
ication. Patient age, sex, height, weight, body mass index
(BMI), and IV site were recorded. All patients were monitored
with electrocardiogram, pulse oximeter, and non-invasive
arterial pressure on arrival at the operating room. Anesthe-
sia was induced with 2.5% thiopental sodium 5 mg/kg. Just
after loss of consciousness, rocuronium 0.6 mg/kg was inject-
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Antihistamine Pretreatment to Reduce Incidence of Withdrawal 
Movement After Rocuronium Injection
The purpose of this study was to determine the effectiveness of antihistamine ther-
apy for withdrawal movements caused by rocuronium injection. One hundred sev-
enty one ASA I-II adults undergoing elective surgery were randomly assigned to
one of two groups. Patients in the control group (Group C) were premedicated with
2 mL normal saline, and those in the antihistamine group (Group A) were pre-medi-
cated with 2 mL (45.5 mg) pheniramine maleate. After the administration of thiopen-
tal sodium 5 mg/kg, rocuronium 0.6 mg/kg was injected. Withdrawal movements
were assessed using a four-grade scale. The administration of antihistamine reveals
lower grade of withdrawal movement after rocuronium injection. 
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Accepted : 22 October 2008ed over 5 sec. Crystalloids were then administered at maxi-
mum gravity flow. Eight patients in group C and 12 patients
in group A were excluded from the study since they received
succinylcholine instead of rocuronium, owing to poor mask
ventilation or complaints of pain during thiopental sodium
administration. To estimate the incidence and degree of the
withdrawal movements associated with rocuronium, patient
response was graded by the investigator according to the fol-
lowing scale proposed by Ahmad and colleagues (1) (Table 1).
Mean arterial pressure (MAP) and heart rate (HR) were record-
ed before the administration of thiopental sodium (baseline),
1 min after injection of rocuronium, and 1 min after tracheal
intubation. Statistical analyses were performed using a statis-
tical package (SPSS 15.0 for Windows, SPSS Inc., Chicago,
IL, U.S.A.). Data was expressed as mean±standard devia-
tion (SD) or as number of patients. Demographic data was
analyzed using a Student’s t-test. The incidence and degree
of movements, and site of IV cannula were compared using
a chi-square test for trend. The incidence of withdrawal move-
ment according to the site of the IV cannula was analyzed
using chi-square test for trend. Hemodynamic variables were
analyzed using a one-way repeated measures ANOVA. P<
0.05 was considered significant.
RESULTS
No significant differences were noted in terms of demo-
graphic variables of patients in Group C and Group A (Table
2). The overall incidence of withdrawal was 84.5% (60/71)
in Group C and 70% (56/80) in Group A, and there were no
significant differences between two groups. The incidence are
greater than expected in grade 3/4 withdrawal movement,
and lesser than expected in grade 1/2 withdrawal movement
in Group C. Group C reveals lesser incidence than expected
value in grade 3/4 withdrawal movement (P=0.008) (Table
3). The overall incidence and grade of withdrawal responses
were independent of the site on the IV cannula (Fig. 1). MAP
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Withdrawal Grade Withdrawal response
1 No response
2 Movement at the wrist only
3 Movement/withdrawal involving arm only (elbow/shoulder)
4 Generalized response
Table 1. Assessment of withdrawal responses
Group C
(Control)
Group A 
(Antihistamine)
Age (yr) 40.7±13.0 42.5±11.9
Gender (M/F) 30/41 33/47
Weight (kg) 62.0±10.7 63.5±13.7
Height (cm) 162.4±9.0 163.6±9.7
Body mass index (BMI) 23.4±2.83 23.7±4.84
Intravascular catheter site 28/23/20 35/22/23
(hand/wrist/forearm)
Table 2. Demographic data of study subjects
Values represent numbers of patients or mean±SD. There were no sig-
nificant differences between two groups.
Fig. 1. Response to administration of rocuronium in patients pre-
treated with antihistamine versus saline depends on intravenous
catheter site. Values represent numbers of patients or withdrawal
grade.
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Grade 1 No response
Grade 2 Movement 
of hand or wrist only
Grade 3 Movement 
involving elbow/shoulder
Grade 4 General response
Group C 
(Control) (n=58)
Grade of withdrawal
movement
Group A 
(Antihistamine) 
(n=62)
1 9 (16%) 15 (24%)
2 3 (5%) 12 (19%)
3 24 (41%) 14 (23%)
4 22 (38%) 21 (34%)
Overall incidence of  49 (84%) 47 (76%)
withdrawal movement
Table 3. Incidence and grade of withdrawal movements during
intravenous rocuronium injection
Values represent numbers of patients and percentage of patient res-
ponse. Under chi-square test for trend, the proportions of observations
on different raws vary from column to column (P=0.008). 
Withdrawal response 1, no movement; 2, movement at hand or wrist
only; 3, movement/withdrawal involving elbow and/or shoulder move-
ment; 4, general response.
Values are mean±SD. No significant differences were noted between
the groups.
BPM, beats per minute.
Baseline
1 min after 
rocuronium
injection
1 min after 
intubation
MAP (mmHg)
Group C (Control) (n=71) 97.2±14.6 103.6±18.9 119.9±22.1
Group A (Antihistamine) 100.5±11.9 102.9±16.7 124.8±21.5
(n=80)
HR (BPM)
Group C (Control) (n=71) 71.8±12.9 92.5±13.3 104.3±12.9
Group A (Antihistamine)  74.7±15.7 90.1±12.7 104.7±13.6
(n=80)
Table 4. Mean arterial pressure (MAP) and heart rate (HR) dur-
ing anesthesia induction
Variables
Variablesand HR during anesthesia induction were not significantly
different between two groups (Table 4). 
DISCUSSION
This study demonstrates that the degree of withdrawal
movement associated with the administration of rocuroni-
um injection can be diminished by pretreatment with an
antihistamine. The incidence of pain associated with rocuro-
nium injection is high; reports suggest that 50-80% of pati-
ents suffer burning sensation (1-3). Withdrawal movements
associated with rocuronium injection may negatively affect
patient outcomes. Withdrawal movements may induce pul-
monary aspiration secondary to gastric regurgitation in uncon-
scious patients (11), cause dislocation or displacement of the
IV catheter, or lead to an emergency situation. The exact mech-
anism of rocuronium-induced pain remains unclear, but it has
been reported that the pain may be due to polymodal noci-
ceptor stimulation caused by the osmolality or pH of the solu-
tion, and/or by the release of endogenous mediators, such as
histamine, bradykinin, kinin and other substances mediating
inflammation (12). Rocuronium is supplied as an isotonic
solution of pH 4, and pain is known to be induced by low pH
injections (13). However, absence of pain in patients receiving
0.9% NaCl adjusted to pH 4 is inconsistent with this hypoth-
esis (12). Several methods have been attempted to reduce this
withdrawal movement and pain, with variable results: pre-
treatment with ondansetron, lidocaine, tramadol, and fentanyl
(3), remifentanil (14) and injection of a mixture of rocuroni-
um and sodium bicarbonate (4, 15). Cheong and Wong (2)
found that both 10 mg and 30 mg of lidocaine given before
the administration of rocuronium significantly reduced the
incidence and severity of pain on rocuronium injection in
adults, and the larger dose was more effective in adult pati-
ents. However, side effects after the pretreatment is possible,
such as anaphylaxis (16), coughing (17), chest rigidity, hy-
potension and bradycardia (18).
The purpose of this study was to determine the effective-
ness of antihistamine pretreatment in reducing pain with-
drawal associated with rocuronium administration. Pheni-
ramine maleate is an alkylamine antihistamine of which mode
of action is achieved by reversible and competitive inhibition
of the interaction of histamine with H1 receptors on cells,
preventing histamine effects on target organs (8). Several stud-
ies have also reported that the analgesic effect of antihistamines
(19-21). Although antihistamine has a similar structure to
lidocaine, allergic cross reactivity has not been reported. Anti-
histamine has been recommended as an alternative analgesics
for the patients who have allergy to lidocaines (22).
After IV administration of pheniramine maleate, peak plas-
ma concentrations are achieved at 15 min (23), with termi-
nal half-lives estimated to range between 8 and 17 hr. We
administrated pheniramine maleate at the time of premedi-
cation, 30 min before induction of anesthesia. Although Dal-
gleish (24) demonstrated that the use of a large vein in the
antecubital fossa is likely to minimize the discomfort caused
to the patient, discomfort did not depend on the site of IV
cannulation in either group in our study. Antihistamine ad-
ministration caused no significant changes in hemodynamic
variables, such as MAP and HR. 
In conclusion, we demonstrated that the degree of with-
drawal reaction can be attenuated by treatment with an anti-
histamine before administration of rocuronium . Patients who
were pretreated with antihistamine were less likely to suffer
pain than those in the control group. 
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